Mexican MoH Aims For Strict Control Of Generics

26 March 1997

For the first time in Mexico, the Ministry of Health is preparing forthe publication of a generic drug register. The idea is to reduce the costs of medicines, and at the same time make it possible for doctors to decide which pharmaceutical products to prescribe without being reliant solely on information provided by claims of the branded market.

Health Minister Juan Ramon de la Fuente announced this at the 18th meeting on Medical Themes, during the Center of Information and Documentation section held at the Spanish Hospital in Mexico City. The Minister said the soon-to-be-released register will be made available to all private physicians and pharmacies throughout the country.

The catalog will clearly state the efficacy of the generics offered, based on research which satisfies questions on quality. The relevant research, the Marketletter's local correspondent points out, is being undertaken by diverse medical divisions of national academic institutions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight